Live Breaking News & Updates on Per Protocol Population

Stay updated with breaking news from Per protocol population. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2B Clinical Trial in CDI Patients

Acurx Pharmaceuticals, Inc. announced positive comparative microbiology and microbiome data for ibezapolstat, its lead antibiotic candidate, from the Company s recently completed Phase 2b clinical. ....

United States , Company Scientific Advisory Board , Data Monitoring Committee , Acurx Pharmaceuticals Inc , Trial Oversight Committee , European Medicines Agency , Acurx Pharmaceuticals , First Quarter , Extended Clinical Cure , Scientific Advisory Board , Clinical Cure , Modified Intent , Treat Population , Per Protocol Population , Prescribing Information , Independent Data Monitoring Committee , Fast Track Designated ,

Acurx Announces Positive Comparative Microbiology and Microbiome Data for Ibezapolstat from Phase 2b Clinical Trial in CDI Patients

Ibezapolstat outperformed vancomycin showing eradication of fecal C. difficile at Day 3 of treatment in 15 of 16 treated patients (94%), versus vancomycin. ....

United States , University Of Houston , Davidp Luci , Kevin Garey , Robertj Deluccia , Acurx Pharmaceuticals , Society Or Healthcare Epidemiology Of America , Company Ph , Company Scientific Advisory Board , Exchange Commission , Data Monitoring Committee , University Of Houston College Pharmacy , Trial Oversight Committee , European Medicines Agency , Drug Administration , Exchange Commission On Form , Acurx Pharmaceuticals Inc , Infectious Diseases Society Of America , Extended Clinical Cure , Gulf Coast Consortia Antimicrobial Resistance , Houston College , Principal Investigator , Acurx Scientific Advisory Board , Double Blind Study , Ibezapolstat Compared , Executive Chairman ,

Acurx Announces Positive Phase 2b Results Showing 100% of Patients Who Had Clinical Cure with Ibezapolstat Also Had Sustained Clinical Cure

All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure at end of treatment remained free of C. difficile Infection recurrence through one month after EOT, for a Sustained. ....

United States , Kevin Garey , Stuart Johnson , Robertj Deluccia , Davidp Luci , Acurx Pharmaceuticals Inc , Infectious Diseases Society Of America , University Of Houston College Pharmacy , Data Monitoring Committee , Exchange Commission On Form , Drug Administration , Company Ph , Trial Oversight Committee , Society Or Healthcare Epidemiology Of America , Exchange Commission , Company Scientific Advisory Board , Loyola University Infectious Disease , European Medicines Agency , Acurx Pharmaceuticals , Prnewswire Acurx Pharmaceuticals Inc , Clinical Cure , Sustained Clinical Cure , Extended Clinical Cure , Houston College , Principal Investigator , Acurx Scientific Advisory Board ,

Acurx Announces Positive Top-Line Ibezapolstat Phase 2 Efficacy Results with 96% Clinical Cure Rate in Patients with C. difficile Infection

In a total of 26 ibezapolstat-treated patients in Phases 2a and 2b, the Clinical Cure rate is 96% Meets protocol primary objective of assessing the primary. ....

United States , Davidp Luci , Robertj Deluccia , Kevin Garey , Stuart Johnson , Peggy Lillis Foundation , Trial Oversight Committee , Data Monitoring Committee , Acurx Pharmaceuticals , C Diff Foundation , Prnewswire Acurx Pharmaceuticals Inc , University Of Houston College Pharmacy , Company Scientific Advisory Board , Drug Administration , Us Centers For Disease , Company Ph , Loyola University Infectious Disease , Acurx Pharmaceuticals Inc , Society Or Healthcare Epidemiology Of America , Exchange Commission On Form , Infectious Diseases Society Of America , Cdiff Foundation , Clinical Cure , Serious Adverse , Sustained Clinical Cure , Extended Clinical Cure ,

Innovation Pharmaceuticals Inc.: Innovation Pharmaceuticals Reports Additional Findings Based on Review of Brilacidin Phase 2 COVID-19 Trial Results and Compassionate Use Cases

WAKEFIELD, MA / ACCESSWIRE / March 7, 2022 / Innovation Pharmaceuticals (OTCQB:IPIX) ("the Company"), a clinical stage biopharmaceutical company, today reported findings from data review of the Company's ....

United States , Proctitis Proctosigmoiditis , Leo Ehrlich , Innovation Pharmaceuticals Inc , Company Brilacidin Phase , Drug Administration , Antiviral Program For Pandemics , Company Compassionate , Exchange Commission , Brilacidin Antiviral Program , National Early Warning Score , Innovation Pharmaceuticals , Brilacidin Phase , Chief Executive Officer , Sustained Recovery Through Day , Intent To Treat Population , Patient Subgroup , Highest Quartile Baseline Values , Per Protocol Population , C Reactive Protein , Load Biomarker , Compassionate Use , Observed Treatment , Brilacidin Oral Mucositis , Ulcerative Colitis , Looking Statements ,